Association between TP53 gene deletion and protein expression in esophageal squamous cell carcinoma and its prognostic significance

Niyaz,Madiniyet; Ainiwaer,Julaiti; Abudureheman,Abulajiang; Zhang,Liwei; Sheyhidin,Ilyar; Turhong,Abduheny; Cai,Ren; Hou,Zhichao; Awut,Edris

doi:10.3892/ol.2020.11709

Association between TP53 gene deletion and protein expression in esophageal squamous cell carcinoma and its prognostic significance

Authors:
- Madiniyet Niyaz
- Julaiti Ainiwaer
- Abulajiang Abudureheman
- Liwei Zhang
- Ilyar Sheyhidin
- Abduheny Turhong
- Ren Cai
- Zhichao Hou
- Edris Awut
View Affiliations

Affiliations: Clinical Medicine Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China, Department of Thoracic Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China
Published online on: June 9, 2020 https://doi.org/10.3892/ol.2020.11709
Pages: 1855-1865
Copyright: © Niyaz et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the association between tumor protein 53 (TP53) gene deletion and protein expression and clinical features in esophageal squamous cell carcinoma (ESCC), and to evaluate the predictive value of these two characteristics in the prognosis of ESCC. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) were performed to detect the expression of p53 protein and gene deletion in ESCC tissue samples from different ethnic groups in Xinjiang, in order to analyze their association with clinicopathological characteristics and patient prognosis, as well as the sensitivity and specificity of the two methods. In addition, the results were further validated by tissue microarray from a different region. The positive rate of p53 protein expression was 54.5% (201/369) in the multi‑ethnic group, and was significantly different between sex (P=0.026) and between tumor differentiation groups (P=0.032). FISH demonstrated that the TP53 gene deletion rate was 31.8% (68/214), which was significantly different between different tumor differentiation (P=0.002), lymph node metastasis (P=0.005) and vascular invasion (P<0.001) groups. The survival rate of patients with TP53 gene deletion was significantly lower than those without TP53 gene deletion (P<0.05). The positive rate of p53 protein expression in the tissue microarray was 58.1% (68/117), which was significantly different between the depth of invasion groups (P=0.011). The TP53 gene deletion rate was 47.9% (56/117), which significantly differed according to lymph node metastasis (P=0.003) and TNM stage (P=0.01). In addition, the total concordance rates of the two methods were 60.3 and 64.1%, respectively. There were also significant differences in the positive rate of TP53 gene deletion and protein expression in different stages of ESCC (P<0.05), which increased gradually with the progression of ESCC. The deletion of the TP53 gene in esophageal cancer was associated with poor prognosis and may be an important biomarker for evaluating the prognosis of patients with ESCC. The combination of FISH and IHC methods could significantly improve the detection rate of TP53 gene abnormalities and the accuracy of prognostic assessment of ESCC.

View Figures

View References

1	Napier KJ, Scheerer M and Misra S: Esophageal cancer: A review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 6:112–120. 2014. View Article : Google Scholar
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
4	Zeng H, Zheng R, Zhang S, Zuo T, Xia C, Zou X and Chen W: Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries. Thorac Cancer. 7:232–237. 2016. View Article : Google Scholar : PubMed/NCBI
5	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
6	Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 23:233–242. 2013. View Article : Google Scholar : PubMed/NCBI
7	Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013. View Article : Google Scholar : PubMed/NCBI
8	Soussi T: The p53 pathway and human cancer. Brit J Surg. 92:1331–1332. 2005. View Article : Google Scholar : PubMed/NCBI
9	Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar : PubMed/NCBI
10	da Silva GN, Evangelista AF, Magalhães DA, Macedo C, Búfalo MC, Sakamoto-Hojo ET, Passos GA and Salvadori DM: Expression of genes related to apoptosis, cell cycle and signaling pathways are independent of TP53 status in urinary bladder cancer cells. Mol Biol Rep. 38:4159–4170. 2011. View Article : Google Scholar
11	Cardin R, Piciocchi M, Tieppo C, Maddalo G, Zaninotto G, Mescoli C, Rugge M and Farinati F: Oxidative DNA damage in Barrett mucosa: Correlation with telomeric dysfunction and p53 mutation. Ann Surg Oncol. 20 (Suppl 3):S583–S589. 2013. View Article : Google Scholar : PubMed/NCBI
12	Di Agostino S, Strano S and Blandino G: Gender, mutant p53 and PML: A growing ‘affaire’ in tumor suppression and oncogenesis. Cell Cycle. 12:1824–1825. 2013. View Article : Google Scholar : PubMed/NCBI
13	Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855–4878. 1994.PubMed/NCBI
14	Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, et al: Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 509:91–95. 2014. View Article : Google Scholar : PubMed/NCBI
15	Huang K, Chen L, Zhang J, Wu Z, Lan L, Wang L, Lu B and Liu Y: Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma. Oncol Lett. 8:1441–1446. 2014. View Article : Google Scholar : PubMed/NCBI
16	Okumura H, Kita Y, Yokomakura N, Uchikado Y, Setoyama T, Sakurai H, Omoto I, Matsumoto M, Owaki T, Ishigami S and Natsugoe S: Nuclear expression of 14-3-3 sigma is related to prognosis in patients with esophageal squamous cell carcinoma. Anticancer Res. 30:5175–5179. 2010.PubMed/NCBI
17	Zhao Z, Wang P, Gao Y and He J: The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamous-cell carcinoma: A meta-analysis. Cancer Med. 6:54–66. 2017. View Article : Google Scholar : PubMed/NCBI
18	Murata A, Baba Y, Watanabe M, Shigaki H, Miyake K, Karashima R, Imamura Y, Ida S, Ishimoto T, Iwagami S, et al: p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma. Med Oncol. 30:7282013. View Article : Google Scholar : PubMed/NCBI
19	Taghavi N, Biramijamal F, Sotoudeh M, Moaven O, Khademi H, Abbaszadegan MR and Malekzadeh R: Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. World J Gastroenterol. 16:4958–4967. 2010. View Article : Google Scholar : PubMed/NCBI
20	Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, Hrstka R, Janotova P, Radina M, Lane DP, et al: Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol. 207:251–259. 2005. View Article : Google Scholar : PubMed/NCBI
21	Halling KC and Kipp BR: Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol. 38:1137–1144. 2007. View Article : Google Scholar : PubMed/NCBI
22	Tafe LJ, Allen SF, Steinmetz HB, Dokus BA, Cook LJ, Marotti JD and Tsongalis GJ: Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas. Exp Mol Pathol. 97:116–119. 2014. View Article : Google Scholar : PubMed/NCBI
23	Egashira A, Morita M, Yoshida R, Saeki H, Oki E, Sadanaga N, Kakeji Y, Tsujitani S and Maehara Y: Loss of p53 in esophageal squamous cell carcinoma and the correlation with survival: Analyses of gene mutations, protein expression, and loss of heterozygosity in Japanese patients. J Surg Oncol. 104:169–175. 2011. View Article : Google Scholar : PubMed/NCBI
24	Bellini MF, Cadamuro AC, Succi M, Proenca MA and Silva AE: Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012:8919612012. View Article : Google Scholar : PubMed/NCBI
25	Edge SB and Compton CC: The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
26	Fagundes RB, Melo CR, Pütten AC, Moreira LF and de Barros SG: p53 immunoexpression: An aid to conventional methods in the screening of precursor lesions of squamous esophageal cancer in patients at high-risk? Cancer Detect Prev. 29:227–232. 2005. View Article : Google Scholar : PubMed/NCBI
27	Muller PA and Vousden KH: p53 mutations in cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
28	Yen CC, Tsao YP, Chen PC, Wu YC, Liu JH, Pan CC, Liu CY, Tzeng CH, Chen PM, Chen YJ, et al: PML protein as a prognostic molecular marker for patients with esophageal squamous cell carcinomas receiving primary surgery. J Surg Oncol. 103:761–767. 2011. View Article : Google Scholar : PubMed/NCBI
29	Wang L, Yu X, Li J, Zhang Z, Hou J and Li F: Prognostic significance of p53 expression in patients with esophageal cancer: A meta-analysis. BMC Cancer. 16:3732016. View Article : Google Scholar : PubMed/NCBI
30	Melling N, Norrenbrock S, Kluth M, Simon R, Hube-Magg C, Steurer S, Hinsch A, Burandt E, Jacobsen F, Wilczak W, et al: p53 overexpression is a prognosticator of poor outcome in esophageal cancer. Oncol Lett. 17:3826–3834. 2019.PubMed/NCBI
31	Yamamoto S, Yashima K, Kawata S, Hosoda K, Tamoto A, Ikebuchi Y, Matsumoto K, Kawaguchi K, Harada K, Murawaki Y and Isomoto H: Frequent aberrant p53 and Fhit expression in endoscopically resected superficial hypopharyngeal cancer and esophageal cancer. Oncol Lett. 14:587–592. 2017. View Article : Google Scholar : PubMed/NCBI
32	Niyaz M, Turghun A, Ping ZH, Zhu Z, Sheyhedin I, Ren C and Awut I: TP53 gene deletion in esophageal cancer tissues of patients and its clinical significance. Mol Med Rep. 7:122–126. 2013. View Article : Google Scholar : PubMed/NCBI
33	Graesslin O, Chantot-Bastaraud S, Lorenzato M, Birembaut P, Quéreux C and Daraï E: Fluorescence in situ hybridization and immunohistochemical analysis of p53 expression in endometrial cancer: Prognostic value and relation to ploidy. Ann Surg Oncol. 15:484–492. 2008. View Article : Google Scholar : PubMed/NCBI
34	Davelaar AL, Calpe S, Lau L, Timmer MR, Visser M, Ten Kate FJ, Parikh KB, Meijer SL, Bergman JJ, Fockens P and Krishnadath KK: Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: A prospective follow-up study. Genes Chromosomes Cancer. 54:82–90. 2015. View Article : Google Scholar : PubMed/NCBI